Status:
COMPLETED
Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
While thoracic radiation therapy (TRT) has been a primary component in successful treatment of a variety of childhood and adult cancers, the exposure to this treatment has been associated with signifi...
Detailed Description
This is an observational study to collect health data from long-term survivors of Hodgkin lymphoma (HL). Data will be collected once at participant enrollment. The long-term effects of thoracic radiat...
Eligibility Criteria
Inclusion
- Inclusion Criteria - HL participant:
- Current St. Jude LIFE protocol Participant, treated with thoracic radiation
- Currently ≥ 18 years of age
- ≥ 10 years from original diagnosis
- Exclusion Criteria - HL participant:
- Has participated in the previous pilot study at St. Jude (HPP16)
- History of cranial or total-body radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment
- Pre-existing known neurocognitive impairment prior to diagnosis of Hodgkin lymphoma
- History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the principal investigators
- Currently pregnant
- Secondary central nervous system neoplasm
- Inclusion Criteria - Normal Control:
- Research participant is a sibling, parent, relative or friend of a current or former St. Jude patient
- Research participant must be at least 18 years of age at the time of the scheduled evaluation
- Exclusion Criteria - Normal Control:
- History of cranial, total-body or thoracic radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment
- Known neurocognitive impairment
- History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the principal investigators
- Currently pregnant
- Central nervous system neoplasm
Exclusion
Key Trial Info
Start Date :
April 26 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 20 2018
Estimated Enrollment :
416 Patients enrolled
Trial Details
Trial ID
NCT01820117
Start Date
April 26 2013
End Date
February 20 2018
Last Update
March 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105